2010 full-year results 3 March 2011 - UCB

More documents

Recommendations

Info

Disclaimer and safe harbour Forward-looking statements: This presentation includes “forward-looking statements” relating to UCB group of companies (“UCB”) that are subject to known and unknown risks and uncertainties, many of which are outside of UCB’s control and are difficult to predict, that may cause actual results to differ materially from any future results expressed or implied from the forward-looking statements. In this presentation, the words “anticipates,” “believes,” “estimates,” “seeks,” “expects,” “plans,” “intends” and similar expressions, as they relate to UCB, are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from such expectations include, without limitation: the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms; the economic environment of the industries in which UCB operates; costs associated with research and development; changes in the prospects for products in the pipeline or under development by UCB; dependence on the existing management of UCB; changes or uncertainties in tax laws or the administration of such laws; changes or uncertainties in the laws or regulations applicable to the markets in which UCB operates. All written and oral forward-looking statements attributable to UCB or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements above. UCB does not intend, or undertake any obligation, to update these forward-looking statements. 2
UCB: to be patient-centric global biopharma leader Focus: Immunology and Central Nervous System R&D spend: 22% of revenue About 203 000 patients treated with UCB’s new core products Operations in more than 40 countries About 8 500 employees globally Stephanie, living with rheumatoid arthritis 3 3
Page 1: 2010 full-year results 3 March 2011
Page 5 and 6: 203 000 patients have now been trea
Page 7 and 8: U.S. Business Greg Duncan, Presiden
Page 9 and 10: Cimzia ® provides a fast response
Page 11 and 12: Cimzia ® in rheumatoid arthritis -
Page 13 and 14: Vimpat ® U.S. When monotherapy is
Page 15 and 16: UCB’s status as the company with
Page 17 and 18: Physicians report Vimpat ® is the
Page 19 and 20: Cimzia ® Fast response for predict
Page 21 and 22: Cimzia ® roll-out in Europe and Re
Page 23 and 24: Vimpat ® in epilepsy Roll-out in E
Page 25 and 26: Neupro ® roll-out in Europe and Re
Page 27 and 28: Neupro ® - rotigotine transdermal
Page 29 and 30: 2010 Financial Performance Detlef T
Page 31 and 32: Net sales of major and new products
Page 33 and 34: Recurring EBITDA Consistent solid u
Page 35 and 36: 2010 cash flows FY 2009 cash € 46
Page 37 and 38: 2011 financial outlook Revenue is e
Page 39 and 40: Advancing the pipeline Iris Loew-Fr
Page 41 and 42: Development pipeline with significa
Page 43 and 44: Brivaracetam in epilepsy New Phase
Page 45 and 46: Additional external pipeline option
Page 47 and 48: UCB NewMedicines strategy and busin
Page 49 and 50: Attrition rates of failed Phase 3 c
Page 51 and 52: UCB2892 (H3 antagonist) January 201
Page 53 and 54:
Significant Pipeline Q2 January pip
Page 55 and 56:
UCB's Sustainable Growth Roch Doliv
Page 57 and 58:
UCB's sustainable future growth Cim
Page 59 and 60:
Appendix 59 59
Page 61 and 62:
Geographic and therapeutic breakdow
Page 63 and 64:
2010 balance sheet € million Cash
Page 65 and 66:
Shareholder structure 1 Strong and
Page 67 and 68:
Cimzia ® in further arthritis indi
Page 69 and 70:
CDP7851 in bone loss disorders Nove
Page 71 and 72:
Vimpat ® in epilepsy Increasing pa
Page 73:
Your UCB Investor Relations team An
show all

2010 full-year results 3 March 2011 - UCB

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?